Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage

Table 3 DFS, OS of XELOX and S-1 in the PSM cohort

	total	event	3 year	5 year	HR(95% CI)^a	p value
Ovarall survival			3-year OS % (95% CI)	5-year OS % (95% CI)
TS-1	110	31	78 (70–86)	72 (64–81)	1	0.240
XELOX	110	20	86 (80–93)	77 (68–88)	0.71 (0.40–1.26)
Disease-free survival			3-year DFS % (95% CI)	5-year DFS % (95% CI)
TS-1	110	38	71 (63–80)	66 (57–75)	1	0.101
XELOX	110	25	79 (72–88)	74 (66–84)	0.65 (0.39–1.09)

^aHR of XELOX adjuvant chemotherapy for recurrence of gastric cancer compared with S-1 as the reference was calculated using Cox’s proportional hazards model
Abbreviations: CI confidence interval, HR hazard ratio. Significant values are in boldface type

ISSN: 1471-2407